Ocugen (OCGN) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
28 Apr, 2026Executive summary
Annual meeting scheduled for June 11, 2026, with voting available online or virtually.
Shareholders are encouraged to review proxy materials and vote by June 10, 2026.
Voting matters and shareholder proposals
Election of Kirsten Castillo and Satish Chandran, Ph.D. as Class III Directors until the 2029 Annual Meeting.
Ratification of PricewaterhouseCoopers LLP as independent registered public accounting firm for 2026.
Advisory vote on executive compensation for named executive officers.
Advisory vote on the preferred frequency of future executive compensation votes.
Other business may be addressed as appropriate during the meeting.
Board of directors and corporate governance
Board recommends all proposals, including director elections and auditor ratification.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Ocugen
- $115M note offering and strong clinical progress extend cash runway, but liquidity risks persist.OCGN
Q1 202611 May 2026 - Shareholders to vote on directors, auditor, executive pay, and annual say-on-pay at 2026 meeting.OCGN
Proxy filing28 Apr 2026 - Shareholders to vote on director elections, auditor, compensation, and a reverse stock split.OCGN
Proxy filing20 Apr 2026 - Shareholders to vote on director elections, auditor, executive pay, and a reverse stock split.OCGN
Proxy filing17 Apr 2026 - OCU410 reduced lesion growth by 31% at 12 months with strong safety and photoreceptor preservation.OCGN
Study update24 Mar 2026 - Advanced gene therapy pipeline, strong clinical data, and cash runway into late 2026.OCGN
Q4 20254 Mar 2026 - Advancing three gene therapies for blindness, with strong early data and extended financial runway.OCGN
H.C. Wainwright – Biotech "On Tap" 202513 Feb 2026 - Gene-agnostic therapies show strong clinical progress and major market potential in retinal diseases.OCGN
Status Update3 Feb 2026 - Gene therapy trials advanced and $32.6M raised, but long-term funding needs persist.OCGN
Q2 20242 Feb 2026